摘要
肝母细胞瘤(hepatoblastoma,HB)是小儿最常见的肝脏原发性恶性肿瘤,90%发生于5岁以内,综合治疗后3年内无事件生存率可达60%~70%。肝内外血管系统癌栓是儿童高危HB临床表现之一,可见于门静脉、腔静脉等中心静脉甚至心房,常诱发上消化道大出血、顽固性腹水、肝脏衰竭等并发症,严重影响肝母细胞瘤患儿的预后。近年来,虽然手术、综合化疗、介入治疗、放疗、射频消融治疗、靶向治疗、高强度射频聚焦刀治疗等均在癌栓方面有所进展,但癌栓依然是难治性HB常见特点之一。该文就近年来儿童HB伴癌栓的临床进展作一综述,旨在提高对此类病例的诊疗质量及改善高危HB的预后。
Hepatoblastoma(HB)is the most common primary malignant liver tumor in children,90%occurs within 5 years old.Its event-free survival rate within 3 years after comprehensive treatment can reach 60%~70%.As one of the clinical manifestations of high-risk HB,tumor thrombus of hepatic and endovascular system can existed in central veins,such as portal vein,vena cava and even atrium.HB often induces massive hemorrhage of upper digestive tract,refractory ascites,liver failure and other complications.It seriously affects prognosis.In recent years,surgery,comprehensive chemotherapy,interventional therapy,radiotherapy,radiofrequency ablation,targeted therapy and high intensity radiofrequency focused knife therapy have made progress.Tumor thrombus is still a common characteristic of refractory HB.In this review,we expound the clinical progress of pediatric HB with cancer thrombus in recent years in order to improve its treatment and prognosis.
作者
孟雪(综述)
黄东生
张谊(审校)
Meng Xue;Huang Dongsheng;Zhang Yi(Department of Pediatrics,Beijing Tongren Hospital,Capital Medical University,Beijing 100176,China)
出处
《国际儿科学杂志》
2020年第5期344-348,共5页
International Journal of Pediatrics
基金
北京市215卫生系统高层次人才项目(2016-03-018)
北京市医院管理中心儿科学协同发展中心重点课题子课题(XTZD20180203)
北京市医管局登峰人才项目(DFL20180201)。
关键词
儿童
肝母细胞瘤
癌栓
Children
Hepatoblastoma
Tumor thrombus
